- Home
- TKNO vs VSTM Comparison
TKNO vs VSTM Comparison
Compare TKNO & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- VSTM
- Stock Information
- Founded
- TKNO 1996
- VSTM 2010
- Country
- TKNO United States
- VSTM United States
- Employees
- TKNO N/A
- VSTM N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- VSTM Health Care
- Exchange
- TKNO Nasdaq
- VSTM Nasdaq
- Market Cap
- TKNO 356.4M
- VSTM 345.6M
- IPO Year
- TKNO 2021
- VSTM 2012
- Fundamental
- Price
- TKNO $4.34
- VSTM $6.01
- Analyst Decision
- TKNO
- VSTM Strong Buy
- Analyst Count
- TKNO 0
- VSTM 9
- Target Price
- TKNO N/A
- VSTM $12.63
- AVG Volume (30 Days)
- TKNO 318.0K
- VSTM 2.3M
- Earning Date
- TKNO 08-07-2025
- VSTM 08-07-2025
- Dividend Yield
- TKNO N/A
- VSTM N/A
- EPS Growth
- TKNO N/A
- VSTM N/A
- EPS
- TKNO N/A
- VSTM N/A
- Revenue
- TKNO $38,250,000.00
- VSTM $10,000,000.00
- Revenue This Year
- TKNO $8.73
- VSTM $55.63
- Revenue Next Year
- TKNO $16.53
- VSTM $453.72
- P/E Ratio
- TKNO N/A
- VSTM N/A
- Revenue Growth
- TKNO 3.79
- VSTM N/A
- 52 Week Low
- TKNO $3.34
- VSTM $2.10
- 52 Week High
- TKNO $10.37
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- TKNO 36.34
- VSTM 60.14
- Support Level
- TKNO $5.03
- VSTM $5.78
- Resistance Level
- TKNO $5.31
- VSTM $6.78
- Average True Range (ATR)
- TKNO 0.35
- VSTM 0.48
- MACD
- TKNO 0.01
- VSTM 0.13
- Stochastic Oscillator
- TKNO 15.75
- VSTM 60.91
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.